GSK, the British pharmaceutical giant, has secured a significant endorsement from the National Institute for Health and Care Excellence (NICE) for its drug Nucala (mepolizumab). The positive recommendation means Nucala will now be available on the NHS for the treatment of severe eosinophilic chronic obstructive pulmonary disease (COPD) in adults in England and Wales. This decision marks a crucial step in providing new treatment options for a subset of patients living with this debilitating respiratory condition.
The guidance from NICE specifies that Nucala is to be used as an add-on maintenance treatment for adults with severe eosinophilic COPD. This applies to patients whose condition remains uncontrolled despite receiving optimal standard care, including triple inhaled therapy. Eligibility requires patients to have had at least two moderate or one severe COPD exacerbation in the past 12 months, and a blood eosinophil count of 150 cells/μL or greater at treatment initiation, or 300 cells/μL or greater in the previous 12 months.
Nucala is a biologic medication administered via injection, and its mechanism of action involves targeting interleukin-5 (IL-5), a cytokine that plays a key role in the production and survival of eosinophils. By reducing the number of eosinophils, the drug aims to decrease the frequency of exacerbations, which are periods of worsening symptoms that often require hospitalisation and can significantly impact quality of life for COPD sufferers.
COPD is a progressive lung disease that makes breathing difficult and is estimated to affect around 3.2 million people in the UK, although many remain undiagnosed. A significant proportion of these individuals experience severe symptoms, with frequent exacerbations leading to substantial healthcare burden and personal suffering. The availability of Nucala on the NHS offers a targeted treatment approach for those patients with an eosinophilic phenotype, a specific characteristic of the disease that responds well to this type of therapy.
This NICE recommendation follows a thorough evaluation of the drug's clinical effectiveness and cost-effectiveness. The process involves considering evidence from clinical trials, expert opinions, and patient testimonies to ensure that new treatments offer value to both patients and the healthcare system. The decision is expected to be welcomed by respiratory clinicians and patient advocacy groups, who have long called for more effective treatments for severe COPD.